New immunotherapy cocktail targets Hard-to-Treat cancers
NCT ID NCT06247956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants with unresectable or metastatic disease will receive the combination. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-8068 (an experimental immunotherapy drug) combined with adebrelimab (another immunotherapy) and platinum-based chemotherapy
What this could lead to
If successful, this could lead to a new first-line treatment option that shrinks tumors more effectively in advanced gastric and esophageal cancers.
What could go wrong
This is an early Phase 2 trial with only 153 participants, so results may not apply to all patients. The combination may cause significant side effects from immunotherapy and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China